OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases
October 07, 2020 09:00 ET
|
OliX Pharmaceuticals
Companies to broaden their existing partnership on Age-related Macular Degeneration (AMD) treatmentsOliX grants Théa worldwide rights excluding Asia-Pacific on OLX301A and OLX301D, targeting dry/wet...
OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
September 29, 2020 15:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Sept. 29, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, presents two virtual posters of their on-going...
OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial
September 24, 2020 21:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Sept. 24, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today the submission of an...
OliX Pharmaceuticals Presents New Data on Asymmetric siRNA Therapy at TIDES: Oligonucleotides and Peptide Therapeutics 2020 Virtual Conference
September 15, 2020 22:30 ET
|
OliX Pharmaceuticals
SUWON, Korea, Sept. 15, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today presented a poster at the TIDES: Oligonucleotides and...
OliX Pharmaceuticals to Present at Global RNAi-Based Therapeutics Summit
July 09, 2020 08:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, July 09, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that Dong Ki Lee, Ph.D., founder...
OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA for the Treatment of Sub-Retinal Fibrosis and Wet Macular Degeneration
June 16, 2020 10:00 ET
|
OliX Pharmaceuticals; LGC Biosearch Technologies Inc.
SUWON, Republic of Korea and LONDON, June 16, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company signed...
OliX Pharmaceuticals Presents at BIO KOREA 2020 International Convention
May 20, 2020 08:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, May 20, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a key player in the development of RNAi therapeutics, today announced that Dong-Ki Lee, Ph.D.,...
OliX Pharmaceuticals Expands Scientific Advisory Board with Addition of Leading Liver Experts
April 17, 2020 08:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, April 17, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a key player in the development of RNAi therapeutics, today announced the appointment of Dr....
OliX Pharmaceuticals and AM Chemicals Announce Exclusive Licensing and Supply Agreement for GalNAc-Conjugation Technology for Liver Targeting
March 30, 2020 08:00 ET
|
OliX Pharmaceuticals
OliX Pharmaceuticals to accelerate the development of effective targeted therapy for liver diseases using AM Chemical’s GalNAc-conjugation technology SUWON, Republic of Korea, March 30, 2020 (GLOBE...
OliX Pharmaceuticals Advances RNAi Approaches to Target Highly Conserved Regions of Coronavirus RNAs
March 20, 2020 10:00 ET
|
OliX Pharmaceuticals
OliX has been developing novel delivery approaches for siRNAs to the lung tissueOliX’s local pulmonary administration of siRNA drugs through nebulization may contribute to improved treatment...